New EHNAC criteria support latest federal legislative rules

The Electronic Healthcare Network Accreditation Commission (EHNAC) announced the adoption of new program criteria that support the latest healthcare reform legislative rules, including the HIPAA omnibus rule.

Following its 60-day public comment period, EHNAC seeks to finalize and adopt enhanced versions of the following programs:

  • DTAAP-CA—Direct Trusted Agent Accreditation Program for Certificate Authorities (V1.1)
  • DTAAP-HISP--Direct Trusted Agent Accreditation Program for Health Information Service Providers (V1.1)
  • DTAAP-RA—Direct Trusted Agent Accreditation Program for Registration Authorities (V1.1)
  • ePAP-EHN—e-Prescribing Accreditation Program (V6.6)
  • EPCSCP-Pharmacy—Electronic Prescription of Controlled Substances Certification Program -- Pharmacy Vendor1 (V1.2)
  • EPCSCP-Prescribing—Electronic Prescription of Controlled Substances Certification Program -- Prescribing Vendor1 (V1.2)
  • FSAP-EHN—Financial Services Accreditation Program for Electronic Health Networks (V2.6)
  • FSAP-Lockbox—Financial Services Accreditation Program for Lockbox Services (V2.6)
  • HIEAP—Health Information Exchange Accreditation Program (V1.4)
  • HNAP-EHN—Healthcare Network Accreditation Program for Electronic Health Networks [Includes Payer] (V10.6)
  • HNAP-Medical Biller—Healthcare Network Accreditation Program for Medical Billers (V1.5)
  • HNAP-TPA—Healthcare Network Accreditation Program for Third Party Administrators (V1.5)
  • MSOAP—Management Service Organization Accreditation Program (V1.4)
  • OSAP—Outsourced Services Accreditation Program2 (V1.5)

As of Jan. 1, 2014, organizations that seek accreditation or re-accreditation must comply with these enhanced criteria standards, according to EHNAC.

Learn more here.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.